



Merus b.v. Licenses Oligoclronics™ Production Technology for Therapeutic Antibody Mixtures

For immediate release: February 10, 2004

Driebergen, The Netherlands – Merus b.v. today announced that it has concluded an agreement with Crucell Holland B.V. to license from Crucell production technology, which, together with Merus' own technology, allows the stable production of mixtures of antibodies by one clonal cell line (Oligoclronics™ Technology).

The development of Oligoclronics™ Technology is based on the observation that individual monoclonal antibodies often are not as efficacious as the body's own polyclonal immune response. Crucell has developed a technology to produce multiple diverse antibodies in one clonal cell line simultaneously and under stable conditions. By combining this technology with its own Oligoclronics™ Technology, Merus believes it will be able to produce novel therapeutic products in a manner that is cost-effective and acceptable to regulatory agencies. The Company also believes that in a number of instances these products will be clinically more efficacious than current generations of monoclonal antibodies.

Dr. Ton Logtenberg, co-founder and CEO of Merus commented: "The technology licensed from Crucell combined with our own intellectual property position provides Merus with a unique and dominant position in this emerging field of antibody technologies. We believe these technologies will permit the development of novel products with increased efficacy for the treatment of infectious diseases, cancer and inflammatory diseases."

Merus Launches Corporate Website

Merus also announced today that it has launched a corporate Website to inform the public and the industry about the Company, Oligoclronics™ Technology and partnering opportunities. The Website can be found at www.merus-biopharm.com or at www.merus.nl.

About Merus b.v.

Merus is a Dutch biotechnology company founded in June 2003 by Ton Logtenberg, Hennie Hoogenboom and Niek Roosdorp. The Company is engaged in the discovery and development of Oligoclronics™ Technology that will permit a novel class of human antibodies, called Oligoclronics™, that are expected to have improved clinical efficacy compared to current generations of human monoclonal antibodies. For more information, please visit our website or contact Dr. Ton Logtenberg, +31-(0)-655-764-221, t.logtenberg@merus-biopharm.com.